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ABSTRACT 
Bone has several crucial functions including mechanical support of movement, 
hematopoiesis, maintenance of mineral homeostasis, and energy regulation. Bone also 
undergoes continuous remodeling to maintain its structural integrity, which suggests it 
has strong respiration and energy consumption capability. It has been shown that during 
development, bones, in particular, osteoblasts, rely on glucose uptake for proper skeletal 
development. However, the effect of energy utilization on osteocytes’ function is 
currently unknown. Osteocytes are terminally differentiated osteoblasts and are deeply 
embedded into the mineralized matrix of bone. Previous studies have shown that PTH 
promotes bone anabolism, in part, by stimulating osteoblasts anaerobic glycolysis while 
suppressing glucose oxidation through the TCA cycle. In osteocytes, PTH suppresses 
Sost expression (the gene encoding a potent inhibitor of bone formation) by inducing 
HDAC4/5 nuclear translocation and MEF2C inhibition. Recently, Scriptaid, an HDAC 
complex inhibitor, has been shown to induce Mef2 expression and exercise-like 
adaptation in mouse muscles. In myocytes, Scriptaid disrupts the HDACs co-repressor 
	  
	   ix 
complex and induces nuclear export of HDAC4/5 with MEF2 activation. This will 
subsequently increase the expressions of several genes related to energy utilization such 
as Glut4 and Pdk4. Thus we hypothesized that Scriptaid might regulate Sost and Glut4 
expression in osteocytes.  
To investigate the effect of Scriptaid on osteocytes, we treated a mouse osteocytic cell 
line, Ocy454-12H, with Scriptaid. Unexpectedly, Scriptaid potently suppressed Sost, 
whereas it increased Glut4 expression. Scriptaid stimulated osteocyte respiration and 
glucose consumption rate. Mechanistically, Scriptaid treatment of Ocy454-12H induced 
nuclear translocation of Hdac5 whereas it did not affect Hdac4. Silencing of Hdac5 
expression with shRNA increased Sost basal expression and blocked Sost suppression 
induced by Scriptaid. However, Glut4 up-regulation by Scriptaid was independent of the 
HDAC4/5-MEF2C pathway. Glut4 luciferase reporter assays demonstrated that two 
additional transcription factors binding sites, O/E&NF1 and C/EBPα, may mediate 
Scriptaid-induced Glut4 up-regulation. Taken together, these data demonstrate that in 
osteocytes Scriptaid suppresses Sost expression through regulating HDAC5-MEF2C 
signaling. However, Scriptaid increases Glut4 expression through Hdac5-independent 
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1 – Introduction 
1.1 - Bone and Osteocytes 
The skeleton is one of the most critical organs in many animals including mammals. In 
humans, bone counts for ~15% of total body weight. Bone has several functions essential 
for animal surviving.  
1. As a rigid tissue, bone has enough mechanical strength protecting soft tissue and 
supporting body locomotion. 
2. Through modeling and remodeling, bones continuously uptake or release mineral ions 
such as calcium and phosphate, which help maintain mineral homeostasis. 
3. Bone marrow cells are the major resource for hematopoiesis. 
4. Apart from those 3 major functions, recent studies also suggest that through secreting 
factors like lipocalin and sclerostin bones regulate other organ metabolism including 
pancreas, fat and muscles.  
Moreover, bone is a rigid connective tissue that consists of cells and the calcified 
extracellular matrix. Bone matrix is composed of organic and inorganic components. The 
inorganic component consists mainly of calcium, phosphate and other inorganic trace 
elements like magnesium, potassium, sodium, fluoride and bicarbonate. The organic 
component is made mainly of type I collagen (90% of the collagenous proteins), bone 
morphogenic proteins (BMPs), osteocalcin (OCN), osteopontin (OPN), bone sialoprotein 
(BSP). Bone contains three different cell types: osteoblasts, the cells in charge of bone 
formation; osteoclast, the cells in charge of bone resorption; and osteocytes, the 
terminally differentiated osteoblasts regulating skeletal homeostasis. Besides, the bone 
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marrow contains marrow adipocytes, endothelial cells, hematopoietic cells, 











Figure 1. The cells in bone tissue  
(Encyclopaedia Britannica Inc, 2013) 
Osteocytes are the most abundant bone cells and account for ~95% of bone cells. The life 
span of these cells is the longest among all bone cells and, in humans, it has been 
estimated that osteocytes can stay alive up to 25 years (Franz‐Odendaal, Hall et al. 
2006). Osteocytes reside in bone lacunae deeply embedded within the mineralized matrix. 
They are terminally differentiated osteoblasts. During the differentiation process, the cells 
undergo extensive changes both in their morphology (acquiring dendrites) and in their 
functions. In the past osteocytes were considered as the late-stage-osteoblasts with no 
major functions, however, studies in recent decades indicate that these cells play an 
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important role as key orchestrators of skeletal homeostasis.  Osteocytes are dendritic cells 
and their dendrites stretch out to connect with other cells. The void bone structure 
accommodating osteocytes and their dendrites is called the lacuno-canalicular system that 
is filled with lacuno-canalicular fluid. This special cell-bone matrix structure helps 
osteocytes to form sophisticated networks that connect with all the cells inside or near the 
bones including osteoblasts, osteoclasts, osteocytes, different hematopoietic cells, 
endothelial cells, endosteal and periosteal cells, and even bone marrow adipocytes. 
Osteocytes secrete numerous endocrine and paracrine factors, including sclerostin, dentin 
matrix protein 1 (DMP1), receptor activator of nuclear factor kappa-B ligand (RANKL), 
osteoprotegerin (OPG), prostaglandin E2 (PGE2), matrix extracellular 
phosphoglycoprotein (MEPE), macrophage colony-stimulating factor (M-CSF), 
phosphate regulating endopeptidase homolog X-linked (PHEX) and fibroblast growth 
factor 23 (FGF23).  These factors are critical for osteocytes functions including 
mechanical sensation and transduction, maintenance of mineral hemostasis, and 



























Figure 2. Osteocyte regulation of bone remodeling through secreted factors 
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Since osteocytes play an important role in skeletal physiology, studying these cells 
becomes a thriving research field. In the past, one critical limitation for osteocyte studies 
was the paucity of available animal or cell models because osteocytes are deeply 
embedded in mineralized bone matrix and difficult to be isolated. Studies in recent years 
provided several models that helped investigators to elucidate osteocyte physiology both 
in vitro and in vivo. The most characterized osteocytic cell line is MLO-Y4 cells 
(Bonewald 1999). This immortalized cell line was derived from a transgenic mouse line 
in which SV40 T-antigen was expressed under control of the osteocalcin promoter. 
Recently, two additional conditional immortalized cell lines were established, Ocy454 
and IDG-SW3, both derived from animals expressing GFP driven by the Dmp1 promoter 
(Woo, Rosser et al. 2011, Spatz, Wein et al. 2015). These cells respond to mechanical 
forces and express high levels of the Sost. In addition, Oc14 cells derived from PTHR−/− 
calvarial bones are also a cell line for in vitro study of osteocytes (Divieti, Inomata et al. 
2001). Primary osteocytes can also be isolated from long bones of adult mice with a 
series of collagenase digestions and demineralizing steps, and they represent a better tool 
to study osteocyte physiology in vitro (Stern, Stern et al. 2012). For in vivo study, 
scientists have generated mice with diphtheria toxin receptor expression under the control 
of the Dmp1 promoter that selectively ablates osteocytes. These osteocyte-less mice have 
an aging skeleton phenotype with fragile bone, intracortical porosity and microfractures 
(Tatsumi, Ishii et al. 2007). Finally, Dmp1-Cre mice crossbred with mice containing loxp 
sites have generated mice with conditional deletion of the targeted gene in osteocytes (Lu, 
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Xie et al. 2007). In summary, these in vitro and in vivo models have made great 
contributions to the field of osteocyte biology.  
1.2 - Sclerostin/Sost Gene 
Sclerostin is a glycoprotein encoded by the Sost gene and is secreted mainly by 
osteocytes. It blocks osteoblast proliferation and differentiation by binding to Wnt co-
receptor, LRP5/6, and blocking its signaling (Baron and Kneissel 2013). Previous studies 
showed that targeted deletion of Sost significantly increases bone volume in mice and 
renders the animals resistant to disuse-induced bone loss (Baron and Kneissel 2013). 
Mutations of the Sost gene or of in its distant enhancer cause two human genetic diseases: 











Figure 3. Wnt signaling and sclerostin inhibition in bone cells  
(Hay E, et al, Gerontology. 2016) 
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Sost expression is also regulated by hormones and cytokines such as parathyroid hormone 
(PTH), BMP, tumor necrosis factor (TNF), vitamin D, androgens and estrogens. It has 
been shown that PTH binds to the PTH receptor (PTHR) and activates adenylyl cyclase 
(AC). The active AC facilitates cAMP production, which, through additional 
intermediate factors, finally blocks MEF2C binding to Sost gene enhancer and results in 
Sost suppression. Moreover, our lab has demonstrated that mechanical loading 
suppressed and microgravity increased Sost expression in osteocytes, which suggests its 
crucial role in osteocyte mechano-transduction (Aune, Ruiz et al.). However, the 
mechanism for osteocyte Sost mechanical regulation is still not well understood. 
1.3 - Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and 
Osteoprotegerin (OPG) 
RANKL is a type II membrane protein and is a member of the TNF superfamily(Hanada, 
Hanada et al. 2011). RANKL is expressed in many organs and tissues including bone, 
skeletal muscle, liver, gut and lung and regulates many functions including the immune 
system and bone remodeling process(Kartsogiannis, Zhou et al. 1999, Wada, Nakashima 
et al. 2006). In bone, RANKL is mainly expressed by osteoblasts and osteocytes as both 
cell membrane surface protein and soluble protein. RANKL binds to its receptor RANK 
expressed on osteoclasts and activates the subsequent signaling. Upon binding, TNF 
receptor-associated factor 6 (TRAF6) is recruited to the receptor and activates c-jun N-
terminal kinase (JNK) and nuclear factor kappa-b (NF-kB), which promotes osteoclasts 
functions and survival. Osteoclast activation plays a crucial role in bone resorption. In 
contrast, OPG, an osteoblast secreted factor, binds to and neutralizes RANKL functions. 
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Thus, the RANKL/OPG ratio is one of the critical indicators of bone status (Khosla 2001, 
Theoleyre, Wittrant et al. 2004). Similar to sclerostin, recent studies indicate that 
RANKL is also regulated by mechanical forces, hormones and cytokines such as PTH, 
Transforming Growth Factor Beta (TGFβ), and Interferon Beta (IFNβ) (Martin and Sims 










Figure 4. RANKL, RANK and OPG in Osteoclast Differentiation/Activation  
(Belibasakis GN & Bostanci N, J Clin Periodontol. 2012) 
1.4 - Dentin Matrix Protein 1 (DMP1) 
DMP1 is an extracellular matrix protein and a member of the small integrin-binding 
ligand N-linked glycoprotein (SIBLING) family. DMP1 was first found in the tooth 
dentin matrix as an important protein for dentinogenesis and maturation (Butler 1995). 
DMP1 is also highly expressed in the bone and has been shown to be critical to skeletal 
mineralization (Qin, D’Souza et al. 2007). It has been shown that during osteogenesis and 
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mineralization DMP1 forms a transient amorphous precursor phase, guiding crystalline 
hydroxyapatite orientation and reinforcement, leading to transformation into a crystalline 
phase and maturation of hydroxyapatite (Ravindran and George 2015). In addition, as 
shown in Figure 5 during the differentiation from mature osteoblasts to osteocytes, Dmp1 
expression rapidly increases when the cells are embedded in mineralized bone matrix. 
Similar to sclerostin and RANKL, DMP1 production is also regulated by mechanical 
forces and hormones such as PTH (Rios, Ye et al. 2005, Buo and Stains 2014). Dmp1 
expression in osteocytes is much higher than in any other tissues. This high expression 
provided the possibility to utilize Dmp1 promoter, to drive the Cre-recombinase 









Figure 5. Osteoblast-to-Osteocyte Differentiation with Marker Genes Expression, Dmp1 Expression 
Rapidly Increase in Mineralizing Osteocyte Stage 
(Bonewald LF, J Bone Miner Res, 2011) 
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1.5 - Matrix Extracellular Phosphoglycoprotein (MEPE) 
Matrix extracellular phosphoglycoprotein (MEPE) is a secreted calcium-binding 
phosphoprotein belonging to the SIBLING family. This protein is encoded by the Mepe 
gene mainly expressed in bone and dentin. Previous studies have shown that MEPE 
contains an RGD motif that helps the protein for integrin recognition (Petersen, Tkalcevic 
et al. 2000). Also, MEPE has been shown to have adverse effect on mineralization and its 
deficiency increases mineralized bone mass (Boskey, Chiang et al. 2010). In addition, 
overexpression of MEPE in mice induces bone mineralization defects with altered bone-
renal vascularization. MEPE-PHEX interactions play a key role in suppression of renal 
calcification (David, Martin et al. 2009). Thus MEPE plays a key role in maintaining 
bone turnover and calcium homeostasis. 
	    
	  










Figure 6. Normal Physiology and Function of MEPE 
(YD Cho, et al, Endocrinology and Metabolism, 2008) 
1.6 - Myocyte Enhancer Factor 2 (MEF2) 
MEF2 is a family of transcription factors (MEF2A, B, C and D) widely expressed in both 
embryonic and adult organs and tissues including neural crest, nerve tissue, skeletal 
muscle, striated muscle, cardiovascular tissue, bone, B cells and Leydig cells (Cain, 
Rueda et al. , Chen, Gao et al. 2017). MEF2 family controls the expression of genes 
important for cellular differentiation, embryonic development and stress 
response(Bastard and Fève). In bone, MEF2, especially MEF2C, has been shown to 
control chondrocyte hypertrophy through an HDAC-PTH mediated mechanism 
(Bonewald). A recent publication showed MEF2C is a critical transcription factor binding 
to a Sost gene enhancer in osteocytes and stimulating Sost expression (Bradner, West et 
al.). Moreover, several studies suggested MEF2 is an important transcription factor that is 
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highly associated with cell metabolism, respiration and energy consumption, especially in 
muscle cells and adipocytes (Knight, Eyster et al. 2003, Henriksson, Säll et al. 2015, 
Gaur, Connor et al. 2016, Gaur, Connor et al. 2017). 
	    
	  








Figure 7. MEF2 mediates PTH regulation of Sost expression in osteocytes  
(Leupin O, et al, J Bone Miner Res. 2007) 
1.7 - Histone Deacetylases (HDACs) 
Histone methylation and acetylation are important biochemical reactions in cells 
regulating gene expression. Histone deacetylase (HDAC) is a family of enzymes that 
remove acetyl groups from acetyl-lysine (K-ac) on histones, allowing the histones to 
wrap the DNA more tightly and block transcription. HDACs are classified into four 
classes depending on sequence homology to the yeast enzymes and domain organization 
(Class I, II, III, IV). Class II is further divided into 2 groups: Class IIa and IIb (Yoon and 
Eom 2016). HDAC 4 and 5 belong to Class IIa HDAC which contains a large C-terminus 
and is found in both cell nucleus and cytoplasm (De Castro, Maycas et al.). HDAC4/5 
can shuttle in or out the nucleus upon different signals in order to control transcription. In 
osteocytes, HDAC4/5 blocks MEF2C and inhibits its function with suppression of Sost 
expression(Bonewald 2011). Moreover, recently two important publications suggested 
that HDAC4/5 active-site mutants or administration of a Class II HDACs inhibitor, 
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Scriptaid, could block HDAC4/5 affinity to MEF2 and simulate exercise-like metabolic 
response in mouse skeletal muscle and cardiovascular tissues, which suggested that 







Figure 8. HDAC5 regulation of Sost expression 











Figure 9. HDAC complex regulation of muscle metabolism 
(V Gaur, et al, Cell Reports, 2016) 
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1.8 - HDAC Inhibitors and Scriptaid 
HDAC inhibitors promote histone acetylation and unwind DNA, which makes the DNA 
sequence available for RNA transcription. In most cases, this inhibition can activate 
several gene expressions, and by regulating these genes HDAC inhibitors can sometimes 
arrest the cell cycle.  
Scriptaid belongs to the hydroxamic class of HDAC inhibitors that have been shown to 
prevent cancer cell growth. Its chemical derivative Vorinostat, related HDAC inhibitor, 
has been approved by FDA for the treatment of cutaneous T cell lymphoma (CTCL) and 
breast cancer (Grant, Easley et al. 2007, Luu, Morgan et al. 2008). The structure of 
Scriptaid is similar to Trichostatin A (TSA), a potent Class I HDAC inhibitor (Marks, 
Rifkind et al. 2001, Damaskos, Valsami et al. 2017). However, a previous study indicated 
that unlike TSA, Scriptaid has a relative weak direct inhibitory capability to HDAC3 
(Class I HDAC) and HDAC4/5 (Class IIa HDAC) (Gaur, Connor et al. 2016). Recent 
studies suggested that Scriptaid acts as an HDAC4/5 complex co-repressor inhibitor 
blocking HDAC4/5-HDAC3-Silencing Mediator of Retinoic Acid and Thyroid Hormone 
receptor (SMRT)-Nuclear Receptor Co-repressor (NCOR) complex formation and 
increasing metabolic genes expression. This increase in energy expenditure simulates 
exercise-like activities in muscle and fat (Gaur, Connor et al. 2016, Gaur, Connor et al. 
2017). It also increases insulin sensitivity in several tissues (Leto and Saltiel 2012). 
1.9 - Parathyroid Hormone (PTH) 
Parathyroid hormone  (PTH), also called parathormone, is a linear polypeptide hormone 
secreted by the parathyroid glands. It is one of the most important hormones in the body 
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regulating calcium homeostasis. The parathyroid glands sense the low serum calcium and 
increase PTH secretion. PTH receptor is a G protein-coupled receptor mainly expressed 
in bone and kidneys. Ligand binding to the PTH receptor can activate subsequent 
signaling, inducing bone catabolic reactions and renal tubular calcium reabsorption. In 
kidney, PTH activates the 1-α-hydroxylase that converts 25-hydroxyvitamin D to 1-α-25-
hydroxyvitamin D3, which is the biologically active form of Vitamin D. This reaction 












Figure 10. PTH Functions and Regulation 
(Vescini F, Grimaldi F. Clin Cases Miner Bone Metab. 2012) 
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1.10 - Glucose Transporter Type 4 (GLUT4) 
GLUT4 is encoded by the Slc2a4 gene, also named Glut4 gene, a member of the solute 
carrier family 2. It is one of 14 members of the GLUT family of transmembrane hexose 
protein complex generally considered as insulin-regulated facilitative glucose transporter, 
which is widely distributed in many tissues and organs including skeletal muscle, fat, 
heart, brain, prostate and bone. In the absence of insulin, GLUT4 is sequestered within 
GLUT4 containing vesicles (GSVs) that localize away from cell membrane surface. 
Under insulin stimulation, phosphorylation of the tyrosine on the insulin receptor induces 
several proteins binding to the cell membrane surface guiding the GSVs translocation to 
membrane surface(Leto and Saltiel 2012, Bakke, Bettaieb et al. 2013). After the fusion 
between GSVs and the cell membrane, the activated GLUT4 proteins stay on the surface 









Figure 11. GLUT4 Protein Activation and Subcellular Translocation 
(Dara Leto & Alan R. Nat Rev Mol Cell Biol. 2012) 
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Previous studies identified GLUT4 as a critical factor associated with diabetes mellitus. 
Sequence analysis of type II diabetes patients’ genomes identified mutations in the 
GLUT4 gene (Mueckler 1993). This suggests GLUT4 may be an important therapeutic 
target for type II diabetes.  
1.11 –	  Salt Inducible Kinase (SIK) 
Salt-inducible kinase (SIK) is a family of serine/threonine protein kinases belonging to 
AMP-activated protein kinases (AMPK). SIK contains 3 family members: SIK1, SIK2 
and SIK3 that share similar molecular structures, including several potential protein 
kinase A (PKA) phosphorylation sites in its long C-terminal extension (Wein, Foretz et al. 
2018). Although SIKs are distributed broadly, the relative expressions of different family 
members in different tissues and organs are distinctive. SIK1 is mainly found in adrenal 
glands, whereas high mRNA levels of SIK2 and SIK3 are present in fat and brain, 
respectively. 
Previous studies have shown that SIK is a critical signaling factor downstream of many 
receptors such as PGE2 receptors (EP2/EP4), PTH receptors (PTHR), β-adrenergic 
receptors and hepatic glucagon receptors (Uebi, Tamura et al. 2010, Clark, MacKenzie et 
al. 2012, MacKenzie, Clark et al. 2013, Wein, Liang et al. 2016). In osteocytes, SIK has 
been shown as a downstream factor that can be phosphorylated and activated by PTHR-
cAMP-PKA signaling, which can then phosphorylate its downstream proteins including 
HDAC4/5 and cAMP-regulated transcriptional coactivator 2/3 (CRTC2/3) that 
respectively regulate Sost and Rankl genes expression (Wein, Liang et al. 2016). In 
adipocytes, a study has shown SIK2 can be activated by β-adrenergic receptors and 
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control Glut4 gene expression through regulating CREB regulated transcription 
coactivator 2/3 (CRTC2/3) and HDAC4 subcellular translocation (Henriksson, Säll et al. 
2015). 
	    
	  









Figure 12. PTH-SIK Signaling in Osteocytes 










Figure 13. β-adrenergic-SIK Signaling in Adipocytes 
(Henriksson E, et al, J Cell Sci. 2015) 
	  
	   21 
1.12 –	  CREB Regulated Transcription Coactivator (CRTC) 
CREB regulated transcription coactivator (CRTC), also known as cytochrome c-type 
(TORC), is a family of transcriptional coactivators highly expressed in specific tissues 
such as liver, heart, skeletal muscles, bone, fat and salivary glands (Conkright, Canettieri 
et al. 2003, Iourgenko, Zhang et al. 2003, Tonon, Modi et al. 2003, Liang, Liu et al. 2016, 
Wein, Liang et al. 2016). 
CRTCs, consisting of CRTC1, CRTC2 and CRTC3, mediate the regulation of important 
transcription factor cyclic-AMP-responsive element-binding (CREB) and its subsequent 
genes function, including metabolic genes like Glut4.  
1.13 -	  G Protein-Coupled Receptor (GPCR) 
GPCR is the largest family of transmembrane receptors in humans. All members of the 
GPCR family share the same structure with 7 transmembrane α–helix domains 
connecting to intracellular G protein binding site on one side and to extracellular receptor 
ligand binding site on the other side(Manglik and Kruse 2017). 
On the intracellular side, the 7 transmembrane domains are associated with heterotrimeric 
G-proteins-complex consisting of Gα, Gβ and Gγ, which are secondary messengers for 
GPCRs. These three G-protein subunits are covalently bonded to the cell membrane. Gα 
contains a domain capable of binding to GTP or GDP, which determines the 
disassociation or association with the Gβ/γ complex. When receptor ligand binds to and 
stimulates GPCR, the receptor induces Gα binding to GTP and disassociating from the 
Gβ/γ complex. The activated Gα and Gβ/γ could respectively activate signaling including 
cAMP-PKA, MEK5, and PI3K signaling. In addition, Gα protein is further classified into 
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4 different Gα proteins: Gαs, Gαi/o, Gαq/11 and Gα12/13, which also respectively induce 











Figure 14. GPCR Activation and Signaling 
(Belmonte SL & Blaxall BC. Circ Res. 2011) 
As one of the most widely distributed receptor family, GPCRs diversely mediate the 
functional regulation in all tissues and organs. In the nervous system, β-adrenergic 
receptor, a member of GPCRs, mediates the sympathetic signaling that controls the stress 
response. Also, PTH receptor, another member of GPCRs, mediates the only known 
mechanism maintaining calcium homeostasis. Osteocytes express several types of 
GPCRs. Studies have indicated some hormones and cytokines such as PTH and PGE2 
bind to their GPCRs on osteocyte membranes. These GPCR-signals regulate several key 
functions in osteocytes (Ciani, Sharma et al. 2014) Activation of these receptors regulates 
numerous transcripts, including Sost, Dmp1 and Rankl, Phex and others. For example, 
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previous studies demonstrated that PTH down-regulates osteocyte sclerostin and DMP1 
and increases RANKL production through activating PTHR.  
1.14 - Clinical & Physiological Relevance 
Scriptaid, whose derivative Vorinostat is an FDA-approved medicine for CTCL (Ozols, 
Herbst et al. 2007), can stimulate muscle cell metabolism and exercise-like energy 
consumption. This finding suggests that apart from its anti-tumor effect, Vorinostat may 
possess other pharmaceutical functions such as controlling obesity, increasing insulin 
sensitivity or maintaining healthy metabolism in long bed-resting patients. Also, Scriptaid 
and its derivative have also been shown to protect the cardiovascular system (Kong, 
Tannous et al. 2006, Natarajan 2011, Gaur, Connor et al. 2017). As Scriptaid’s 
mechanism is closely related to HDAC4/5 and MEF2 activity, it may also have effects on 
bone and osteocytes. 
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2 – Rationale, Hypothesis and Aims 
2.1 - Rationale 
In skeletal muscle, Scriptaid, a Class II HDAC complex inhibitor, blocks HDAC4/5 
complex formation and activates MEF2. This reaction stimulates metabolic genes 
expression especially Glut4 and also increases cell respiration. 
In osteocytes, HDAC4/5 bind to an inhibit MEF2C and suppress Sost gene expression. 
2.2 - Hypothesis 
In osteocytes, Scriptaid activates MEF2C. This increases metabolism and suppresses Sost 
expression of osteocytes, which might have a profound effect on energy utilization and 
skeletal homeostasis. 
2.3 – Aims 
! Study of the effects of Class II HDAC complex inhibitor Scriptaid on osteocyte 
metabolism. 
! Study of the Scriptaid effects on osteocyte bone remodeling genes regulation. 
! Study of the Scriptaid effects on bone explants and primary osteocytes 
! Exploring the underlying mechanisms that mediate Scriptaid regulation of osteocyte 
metabolism and bone remodeling genes expression. 
3 – Objective 
Study the effects of Scriptaid on osteocyte metabolism and skeletal homeostasis 
regulation in vitro and ex vivo. Also further explore the underlying mechanisms 
mediating Scriptaid effects. 
	  
	   25 
 
4 – Materials and Methods 
4.1 - Compounds and Antibodies 
Scriptaid was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).  
Trichostatin A and MC1568 were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Synthetic Human PTH(1-34) peptide was kindly provided by Dr. Ashok Khatri 
(Peptide/Protein Core Facility, Partners Research Core & Massachusetts General Hospital, 
Boston, MA, USA).  
Primary antibodies against GLUT4 (cat# 2213), HDAC5 (cat# 20458), MEF2C (cat# 
5030), H3K9ac (cat# 9649), and β-Tubulin (cat# 5346) were purchased from Cell 
Signaling Technology (Danvers, MA, USA). HDAC4 (cat# ab12172) antibody was 
purchased from Abcam (Cambridge, MA, USA). SP1 (cat# 07-645) and CRTC2 (cat# 
ST1099) antibodies were from EMD Millipore (Burlington, MA, USA) 
For secondary HRP-coupled antibodies, anti-rabbit IgG (cat# 7074) was purchased from 
Cell Signaling (Danvers, MA, USA) and anti-mouse IgG (cat# sc-516102) was purchased 
from Santa Cruz (Dallas, TX, USA) 
4.2 - Ocy454-12H Cell Line Generation and Culture 
Ocy454-12H cells were generated from single-cell cloning of high GFP–expressing 
Ocy454 cells and screened for high sclerostin expression as recently reported (Spatz, 
Wein et al. 2015, Fulzele, Lai et al. 2017). Cells were routinely maintained on non-
collagen-coated cell culture flask (Corning, Corning, NY, USA) in α-Minimum Essential 
Medium (αMEM) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) 
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and 1% antibiotic-antimycotic (αMEM complete medium) (Gibco, Gaithersburg, MD, 
USA). For all cell culture experiments, cells were plated at 100,000 cells/ml in 6-well (2 
ml/well), 12-well (1 ml/well) or 24-well (0.5 ml/well) plates or 10 cm tissue culture 
dishes (10 ml/dish) and allowed to reach confluence at 33°C for 3 to 4 days, prior to be 
moved to 37°C and cultured for the indicated time to induce differentiation. 
4.3 - Osteocyte-Enriched Bone Explants (OEBE) 
Osteocyte-enriched bone explants (OEBE) were generated from calvaria isolated from 4-
week old wild type C57BL6 female mice purchased from Charles River Laboratories 
(Wilmington, MA, USA). In brief, after 1-day of acclimatization, mice were sacrificed 
and calvaria were aseptically isolated, washed in PBS and sequentially digested in 
αMEM containing collagenase (1 mg/ml of Collagenase Type I: II ratio = 1: 4; 
Worthington Biochemical Corporation, Lakewood, NJ, USA); 1 mM CaCl2; 10 mM 
HEPES (Life Technologies, Camarillo, CA, USA) to remove periosteal and endosteal 
osteoblasts. Calvarial explants were cultured overnight at 37°C in 5% CO2 in complete 
αMEM. 6 hours before RNA extraction, calvarial bones were cut into 2 halves through 
the sagittal suture and randomly distributed into 4 groups: 10 µM Scriptaid, 100 nM 
hPTH(1-34), DMSO (as vehicle for Scriptaid) and complete medium (as vehicle for 
PTH). After 6 hours of treatment, OEBEs were homogenized and RNA was extracted as 
described below. 
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 4.4 – Primary Osteocyte Isolation and Culture 
Primary osteocytes isolation and culture in vitro were performed following a previously 
published protocol (Stern, Stern et al. 2012). In brief, 4-week old C57BL6 wild type male 
mice were sacrificed and humeri, femora, tibia were aseptically dissected and collected 
for primary osteocytes isolation. All the bones from the same mouse were collected as 
one sample and placed in αMEM with 10% FBS and 1% antibiotic-antimycotic. 
Epiphyses of the bones were cut off and bone marrow was flushed out with PBS. The 
bone diaphysis were cut lengthwise and then cut into 1-2 mm lengths. The bone 
fragments underwent 4 times of alternate 20 min collagenase (1+2) digestion and 20 min 
EDTA (5mM EDTA in PBS) followed by a final 20 min collagenase digestion, for a total 
of 4 digestions. The bone fragments were collected into one well of a 6-well plate and 
cultured in complete αMEM for 7 days in a 37oC incubator (αMEM changed twice per 
week). The primary osteocytes migrated from the bone fragments and attached to the 
bottom of the well. When cells become 95%-100% confluent, the cells were trypsinized 
and re-plated into new 12-well plates at the concentration of 1×105 cell/ml and cultured 
with complete αMEM (αMEM changed twice per week) in 37oC incubator until the cells 
were ~100% confluent (~21 days) with medium changed twice per week, and then treated 
with various chemicals. 
4.5 - Quantitative Real-Time PCR 
For cell culture, experiments total RNA was isolated using RNAeasy Plus Mini Kit 
(Qiagen, Germantown, MD, USA) and quantified using NanoDrop 2000 (Thermo Fisher 
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Scientific). First-strand cDNA was generated using qScript cDNA SuperMix (Quantabio, 
Beverly, MA, USA) and 500~1000 ng of total RNA.  
For OEBE experiments, bone explants were homogenized in TRIzol (Thermo Fisher 
Scientific, Waltham, MA, USA) using a tissue homogenizer (TissueLyser, Qiagen, 
Qiagen, Germantown, MD, USA). Total RNA was isolated using the PureLink RNA 
Mini Kit (Ambion, Life Technologies, Camarillo, CA, USA). cDNA was synthesized 
with Takara PrimeScript RT Reagent Kit plus gDNA Eraser (Clontech, Mountain View, 
CA, USA) and 250~1000 ng of total RNA. 
Realtime qPCR was performed using SYBR Green Master Mix (Thermo Fisher Scientific, 
Waltham, MA, USA) in a StepOnePlus Real-Time PCR system (Applied Biosystems). 
Target genes were normalized to the housekeeping gene, β-Actin. Primer sequences are 
listed in Table 1. 
Gene Forward Reverse 
β-Actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 
Glut4 CCAGCCTACGCCACCATAG TTCCAGCAGCAGCAGAGC 
Glut1 CAGTTCGGCTATAACACTGGTG GCCCCCGACAGAGAAGATG 
Pdk4 TGTGATGTGGTAGCAGTAGTC ATGTGGTGAAGGTGTGAAGG 
Cs CAAAGCTCCTGCCTGTGTTTG GGGTTTACAGTGTGTCCATCTCAA 
Atp5d ACACAGAAGACGGCACCA GCACAGAGGAGTCGGCATTC 
HkII TGCCAAGCGTCTCCATAA CGGAGGAAGCGGACATCA 
Sost CTTCAGGAATGATGCCACAGAGGT ATCTTTGGCGTCATAGGGATGGTG 
Rankl GCTGGGCCAAGATCTCTAAC GTAGGTACGCTTCCCGATGT 
Mepe GTCTGTTGGACTGCTCCTCTT CACCGTGGGATCAGGATACA 
Opg ACCCAGAAACTGGTCATCAGC CTGCAATACACACACTCATCACT 
Dmp1 AAGCTAGCCCAGAGGGACAGGCAA TTATCGGCGCCGGTCCCCGTAC 
Mef2c CCACTGGCCCACCCGTCTCT GTGAGTTCCGGGGGTTGCCG 
Hdac4 CACATGCCCAGCACGGTGGA TGCTGCAGTTGCTGCTCCCG 
Hdac5 AGCACCGAGGTAAAGCTGAG GCTGTGGGAGGGAATGGTT 
Sik2 CTGCTGGCAACATGGTGTG GGGAGAGTTGGTCCATCAAAAG 
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Crtc2 CCATAGTCACCCATCACTGC GCACTCAGGACAGGAGATGA 
Hdac1 AGTCTGTTACTACTACGACGGG TGAGCAGCAAATTGTGAGTCAT 
Hdac2 GGAGGAGGCTACACAATCCG TCTGGAGTGTTCTGGTTTGTCA 
Hdac3 GCCAAGACCGTGGCGTATT GTCCAGCTCCATAGTGGAAGT 
Table 1. Genes primer sequences for real-time qPCR 
  
4.6 - Western blot, Immunoprecipitation and Subcellular Protein Fractionation 
Whole cell lysates were prepared in ice-cold lysis buffer (1%Triton X-100, 50mM Tris-
base, 1mM EDTA, 1.5mM MgCl2, 150mM NaCl, 10% Glycerol) with 10% 10X protease 
inhibitor cocktail and 2% phosphatase inhibitor cocktail 2 and 3 mixture (Sigma-Aldrich, 
St. Louis, MO, USA) according to the manufacturer’s recommendations. Protein 
concentrations were quantified with Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, 
USA). Protein lysates (20 µg) were heated in Laemmli SDS reducing sample buffer 
(Boston BioProducts, Ashland, MA, USA) at 95oC for 5 min. The proteins were 
separated in 7–10% polyacrylamide denaturing gels (Life Technologies, Camarillo, CA, 
USA) and transferred to PVDF membranes using the Trans-Blot Turbo (Bio-Rad, 
Hercules, CA, USA) system according to the manufacturer’s recommendations. The 
membranes were blocked with 5% BSA or 5% nonfat milk in Tris-buffered saline 
containing 0.1% Tween 20 (TBST) at room temperature for 1 hour and then incubated 
with primary antibodies overnight at 4°C at the manufacturer’s recommended 
concentration (1:500~1:1000 dilution). After washing, the secondary antibody was 
incubated for 1 h at room temperature according to the manufacturer’s recommendations 
(1:500~1:2000 dilution) and the blot was developed using enhanced chemiluminescence 
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(Thermo Fisher Scientific, Waltham, MA, USA) or SuperSigna West Femto 
Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA).  
For immunoprecipitation, whole cell lysates were isolated from cells cultured in 10-cm 
dishes (Corning, Corning, NY, USA) with TNT lysis buffer (200mM NaCl, 20mM Tris-
HCl pH 8, 0.5% Triton X-100) supplemented with protease and phosphatase inhibitors 
cocktail 2 and 3 (Sigma-Aldrich, St. Louis, MO, USA). Lysates were pre-cleared with 
protein A/G agarose beads (Pierce, Thermo Fisher Scientific, Waltham, MA, USA), and 
3 mg of total proteins in 800 µl lysis buffer were incubated with 5-6 µl of antibody at 4oC 
overnight. The next day, targeted protein complexes were precipitated with the beads and 
washed 3-4 times in cold TNT buffer. The proteins were eluted in 60 µl of Laemmli SDS 
reducing sample buffer (Boston BioProducts, Ashland, MA, USA) at 95oC for 5 min and 
20 µl of the samples were separated in 7–10% Polyacrylamide denaturing gels and 
detected as described above. 
The nuclear and cytoplasmic fractions of protein lysates were isolated using a 
commercial kit (NE-PER #78833, Thermo Fisher Scientific, Waltham, MA, USA). 20 µg 
of the samples were used for Western Blot analysis as described above. 
4.7 – Global Histone 3 Acetylation Assay 
The global H3 acetylation assays were performed using the Global Histone H3 
Acetylation Assay Kit (Epigentek, Farmingdale, NY, USA). In brief, Ocy454-12H cells 
plated in a 12-well plate at 1×105 cells/ml and after 10 days in culture, cells were 
trypsinized and collected after chemical treatment. After washed with PBS the cells were 
lysed and histones were extracted and purified.  After quantification, 2 µg of histone 
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proteins were incubated with the capture and detection antibody. The absorbance of 
OD450 value was read in the TriStar LB941 microplate reader (Berthold Technologies, 
Oak Ridge, TN, USA). The relative histone acetylation percentage was calculated using 




4.8 – Cell Bioenergetics and Mitochondrial Stress Test (Seahorse XF) 
Ocy454-12H cells were plated in 96-well Agilent Seahorse XF Cell Culture Microplate at 
20,000 cells/well (Agilent, Santa Clara, CA, USA) and cultured in αMEM complete 
medium (as described above) at 33°C in a humidified 5% CO2 incubator for 4 days. On 
the experimental day, the cells were treated with Scriptaid, PTH or DMSO (vehicle), at 
the indicated concentration for 4 hours prior to analysis with Seahorse XFe 96 analyzers 
(Agilent, Santa Clara, CA, USA) following the manufacturer’s recommendation (Gaur, 
Connor et al. 2016). After sequentially injected oligomycin, p-
trifluoromethoxyphenylhydrazone (FCCP) and antimycin, cells were restricted or 
stimulated to specific respiration status. Oxygen consumption rates (OCR) were 
automatically measured by the analyzer through each period and respiration and energy 
production capability were calculated. CyQuant (Thermo Fisher Scientific) was used to 
normalize for cell number by measuring DNA concentration. 
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4.9 – Glucose Uptake Assay 
Glucose Uptake Cell-Based Assay Kit (Cayman Chemical, Ann Arbor, MI, USA) was 
used to measure glucose uptake, following the manufacturer’s recommendation. Briefly, 
cells were plated in 96-well black plates with clear bottom at 20,000 cells/well in αMEM 
complete medium at 33°C overnight. The next day the cells were cultured in no-Glucose 
Dulbecco's Modified Eagle Medium (DMEM) (#11966025, Gibco, Gaithersburg, MD, 
USA) and treated for 4 hours with Scriptaid, PTH or DMSO (vehicle) at the indicated 
concentration. At the end of the treatment, fluorescent deoxyglucose derivative (2-NBDG) 
was added to each well to a final concentration of 100 µg/ml and the cells were incubated 
for an additional 1 hour. Glucose uptake was measured at 485 nm-excitation/535 nm-
emission using Tecan Infinite M1000 Microplate Reader (Tecan, Switzerland). 
Fluorescence intensity was normalized with the protein content in each well. 
4.10 – shRNA Gene Silencing and CRISPR/Cas9 Gene Deletion 
The shRNA and CRISPR/Cas9 techniques were used to generate Ocy454 cells with genes 
silencing or deletion of targets described below (Wein, Spatz et al. 2015, Wein, Liang et 
al. 2016). The sequences for shRNA and CRISPR-Cas9 gRNAs are listed in Table 2. 
Briefly, for shRNA, the target sequences were cloned into PLKO.1-puro backbone (gift 
from Bob Weinberg, Addgene #8453, Cambridge, MA, USA) (Stewart, Dykxhoorn et al. 
2003) and plasmids were amplified in One Shot Stbl3 Chemically Competent E. coli cells 
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) following manufacturer’s 
recommendation. HEK 293T cells were plated at 440,000 cells/well in 6-well plates and 
after 24 hours transfected with shRNA plasmid along with pMD2.G (gift from Didier 
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Trono, Addgene #12259, Cambridge, MA, USA) and psPAX2 (gift from Didier Trono, 
Addgene #12260, Cambridge, MA, USA) using FuGENE-HD (Promega, Madison, WI, 
USA) following manufacturer’s protocol. Complete αMEM was changed 24 hours after 
transfection and collected 48 hours later. Ocy454-12H cells were exposed to medium 
containing lentivirus particles and polybrene (8 µg/ml) overnight at 33oC. The medium 
was replaced every day with fresh complete αMEM containing puromycin (4 µg/ml) to 
efficiently transfected cells. The cells were maintained in complete αMEM medium with 
puromycin (4 µg/ml) at 33oC. 
For CRISPR-Cas9 Gsα gRNAs targeting GNAS exon 1 and 2 were cloned into pSpCas9 
(BB)-2A-GFP (PX458) (gift from Feng Zhang, Addgene #48138, Cambridge, MA, 
USA)(Ran, Hsu et al. 2013) which co-expressed Cas9, sgRNA and eGFP. Empty vectors 
were used to generate controls. Ocy454 cells were cultured in a 6-well plate with initial 
concentration at 200,000 cells/well and kept at 33ºC. After 48 hours, the cells were 
transfected with 1 µg of the plasmid. 48 hours after the transfection, eGFPhi cells were 
sorted by FACs and single cells were plated in 96-well plates. The αMEM complete 
medium was changed every 3~4 days until the colonies were formed. The cells were 
trypsinized and transferred to cell culture flasks (Corning, Corning, NY, USA) and 
maintained in culture as described above. 
shRNA Sequence 
 Hdac5 CATCGCTGAGAACGGCTTTAC 
 Sik2 CTTGTTGGTGGAACGTCTAAA 
 Crtc2 CAAGGTGTAGAGGGAAATCTT 
 C/ebpα AAAGCCAAACAACGCAACGTG  
Mef2c CCAGCTTTGAGATGCCAGTTA  
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sgRNA Sequence #1 Sequence #2 
Hdac4 TGACGTGTAGAGAGGAAGTG ACTTACCCATACCAGTAGCG 
Gnas CCTCGGCAACAGTAAGACCG GATCCTCATCTGCTTCACAA 
Table 2. shRNA and CRISPR-Cas9 sgRNA Target Sequences 
 
4.11 – Transient Transfections and Luciferase Reporter Assays 
Transient transfection of luciferase reporter plasmids was performed in the Ocy454-12H 
cell line using FuGENE-HD (Promega, Madison, WI, USA) according to manufacturer’s 
protocol. In brief, the synthetic mouse DNA sequences containing different lengths of 
mouse Glut4 gene promoter sequences were cloned into pGL3-Basic Luciferase Reporter 
Vectors (Promega, Madison, WI, USA). Full length (-1294 to +34 bp) or truncated Glut4 
promoters in the pGL3 firefly luciferase plasmids were co-transfected with Renilla 
luciferase plasmids driven by CMV or TK promoter (GLUT4-Luciferase: 
Renilla=25:1~50:1) at 500 ng of total DNA quantity. 24 hours after the transfection, 
culture medium was replaced by fresh complete αMEM containing the indicated 
chemicals and 4 hours later luciferase assays were performed and quantified using the 
Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the 
manufacturer’s protocol.  
For promoter sequence mutations and deletions, primers were designed with 
NEBaseChanger™ tool and the Q5 mutagenesis kit (New England Biolabs, Ipswich, MA) 
was utilized to perform mutated PCR according to manufacturer’s protocol. Mutant 
plasmids were transfected in Ocy454-12H cells and assayed for Luciferase as described 
above. 
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4.12 – Statistical Analysis 
Data are presented as means ± SD. Statistically significant differences were determined 
by the unpaired-T test, one-way ANOVA or two-way ANOVA using Prism (GraphPad 
Software, La Jolla, CA, USA). Values of P<0.05 were accepted as significant. The 
experiments were conducted in duplicate or triplicate unless otherwise specified in the 
figure legends. 
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5 – Results 
5.1 – Effects of Class II HDACs complex inhibitor Scriptaid on osteocytes 
metabolism 
5.1.1 – Scriptaid, PTH and Other HDAC Inhibitors Effects on Osteocytes Metabolic 
Genes 
Previous studies demonstrated that Scriptaid induces myocytes adaptive responses 
through increasing metabolic genes expression (Gaur, Connor et al. 2016, Gaur, Connor 
et al. 2017), and glucose and lipid utilization. We sought to examine if Scriptaid 
increased cell respiration and metabolism in osteocytes. The data showed that Scriptaid 
enhanced histone 3 lysine 9 acetylation (H3K9ac) and global histone 3 acetylation (Fig. 
15A-C), confirming its activity. 
Scriptaid significantly increased the expression of Glut4, the gene involved in glucose 
uptake (Fig. 15D), pyruvate dehydrogenase kinase 4 (Pdk4), the gene related to lipid 
metabolism (Fig. 15E), and ATP synthase subunit delta (Atp5d) that associated with the 
mitochondrial activity (Fig. 15F). The drug did not significantly regulate citrate synthase 
(Cs) and hexokinase II (HkII) that participate in the TCA cycle (Fig. 15G-H).  Scriptaid 
had no effect on glucose transporter type 1 (Glut1) expression, which is essential for 
osteoblast anabolic function (Fig. 15I). Taken together these data suggest Scriptaid 
increases cell metabolic genes expression in osteocytes similarly to its effect on muscle 
and fat cells.  
Parathyroid hormone (PTH) is secreted by the parathyroid glands and it maintains 
calcium and phosphate homeostasis and bone modeling and remodeling. PTH exerts its 
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anabolic effect on bone, partially by stimulating osteoblast glucose utilization and 
metabolism (Esen, Lee et al. 2015). Thus, we sought to explore the PTH regulation of 
osteocyte metabolism. Consistent with the previous data, treatment with PTH did not 
have a significant effect on H3K9 or global histone 3 acetylation in Ocy454-12H cells 
(Fig. 15A-C). However, it moderately but significantly increased the expression of 
metabolic genes including Glut4, Pdk4 and Atp5d (Fig. 15J-L) and insignificantly 
increased Cs (Fig. 15M). 
Similar results were observed when Ocy454-12H cells were treated with trichostatin A 
(TSA), a selective class I HDAC inhibitor, whereas MC1568, a class II-a-specific 
inhibitor, had no significant effect (Fig. 15N-Q). Collectively, these data indicated that 
Scriptaid, PTH and TSA, but not MC1568, enhance the expression of genes linked to 
lipid and glucose utilization in osteocytes. This suggests Scriptaid may not act as a Class 
II HDAC inhibitor when it is administered to osteocytes. 
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Figure 15. Metabolic genes regulation by Scriptaid, PTH and other HDAC inhibitors in Ocy454-12H 
Cells 
 (A) Western blot analysis for H3K9ac in Ocy454-12H cells treated with Scriptaid (10 µM) or PTH (50 nM) 
for 30 min prior to protein isolation. Loading was normalized to tubulin, MW=molecular weight. (B) 
Quantification of H3K9ac, normalized to tubulin. (C) Quantification of global histone 3 acetylation assay 
for Ocy454-12H cells treated with Scriptaid (10 µM) or PTH (50 nM) for 30 min, normalized to vehicle. 
(D-I) Real-time qPCR for Glut4, Pdk4, Atp5d, Cs, HkII and Glut1 in Ocy454-12H cells treated with 
Scriptaid  (1 µM) for 4 h. Expression was normalized to β-actin.  (J-M) Real-time qPCR for Glut4, Pdk4, 
Atp5d and Cs in Ocy454-12H cells treated with PTH (1 nM) for 4 h, relative to β-actin. (N-Q) Ocy454-12H 
cells were treated with TSA (1 µM) or MC1568 (1 µM) for 4 h prior to RNA isolation. Real-time qPCR for 
Glut4, Pdk4, Atp5d and HkII in cells treated with TSA or MC1568, relative to β-actin. One-way ANOVA 
was performed with the vehicle as the comparison group for (B-C, N-Q). Unpaired t-tests were performed 
for (D-M). For the bar graphs, n=3 and *p<0.05 and **p<0.01.  Data are expressed as means ± SD. 
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5.1.2 –Dose Response of Osteocytes Metabolic Genes to Scriptaid Treatment 
To investigate if Scriptaid regulation of osteocyte metabolic genes is dose-dependent, 
Ocy454-12H cells were treated with different doses (10 nM, 100 nM, 500 nM, 1 µM and 
10 µM) of Scriptaid for 4 hours and the expression of key genes was analyzed. Scriptaid 
increased Glut4 and Pdk4 expression (Fig. 16) in a dose-dependent manner. The dose-
response analysis demonstrated that 500 nM of Scriptaid was sufficient to significantly 
up-regulate Glut4 and Pdk4 expression. This indicated the effects of Scriptaid on 








Figure 16. Metabolic genes dose response to Scriptaid 
Ocy454-12H cells were treated with Scriptaid prior to RNA isolation. Real-time qPCR for Glut4 and Pdk4 
dose response in cells treated with Scriptaid for 4 h, normalized to vehicle. One-way ANOVA was 
performed with the vehicle as comparison.  For all graphs n=3 and *p<0.05; **p<0.01 and *** p<0.001, 
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5.1.3 – Scriptaid and PTH Effects on Osteocytes Cell Respiration and Glucose 
Utilization 
To validate the treatment of Scriptaid or PTH affecting osteocyte functions, western blot 
analysis was used to detect the key metabolic protein expression. Both Scriptaid and PTH 











Figure 17. Regulation of cell GLUT4 protein expression by Scriptaid and PTH 
Ocy454-12H cells were treated with Scriptaid or PTH prior to protein isolation (A-D) or function assays 
(E-L). Western blot analysis for GLUT4 in cells treated with Scriptaid (1 µM,10 µM) (A) or PTH (10 nM) 
(C) for 6 h, MW=molecular weight. The loading was normalized by tubulin. (B&D) Quantification for 
GLUT4, relative to tubulin. One-Way ANOVA was performed for (B) and the vehicle-treated cells as the 
comparison. An Unpaired t-test was performed for (D). For all graphs, n=3 and *p<0.05, data are expressed 
as means ± SD. 
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To further analyze osteocyte cell respiration and oxidative phosphorylation capability, 
Ocy454-12H cells were treated with Scriptaid or PTH for 4 hours before cell 
mitochondrial stress test. Both Scriptaid and PTH significantly increased osteocytes basal, 
maximal and non-mitochondrial respiration and ATP production (Fig. 18A-E). In 
addition, both chemicals did not significantly increase spare respiratory capability (Fig. 
18F). Interestingly, Scriptaid increased osteocyte proton leakage, whereas PTH had no 
significant effect (Fig. 18G). Also, glucose uptake capability was significantly increased 
in Ocy454-12H cells upon Scriptaid administration whereas PTH stimulation only 
marginally, but not significantly, stimulated glucose utilization (P=0.07) (Fig. 18H). In 
summary, these data showed that Scriptaid can stimulation cell respiration and glucose 
utilization in osteocytes at the functional level. 
	    
	  















Figure 18. Regulation of Ocy454-12H cells respiration and glucose utilization by Scriptaid and PTH 
Ocy454-12H cells were treated with Scriptaid or PTH prior to functional assays. (A) Mitochondrial 
function assays for respiration oxygen consumption rate (OCR) in cells treated with Scriptaid (1 µM) or 
PTH (10 nM). (B-G) Quantification for OCR in basal respiration, maximal respiration, non-mitochondrial 
respiration, ATP production, spare respiratory capability and proton leak, normalized to the vehicle-treated 
cells. (H) Glucose uptake assays for cells treated with Scriptaid (10 µM) or PTH (50 nM) for 4 h. One-way 
ANOVA was performed for (B-H) and the vehicle-treated cells as comparison.  For all graphs n=3 and 
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5.2  – Study of Scriptaid effects on bone remodeling genes in osteocytes 
5.2.1 – Scriptaid Effects on Skeletal Homeostasis Genes Expression in Osteocytes 
In myocytes, Scriptaid blocks the formation of the HDAC co-repressor complex 
containing HDAC4/5, HDAC3, NCOR and SMRT, thus releasing and reactivating the 
transcriptional activity of MEF2 which promotes transcription of several genes, including 
Glut4. In osteocytes, PTH induces HDAC4/5 nuclear translocation and suppresses 
MEF2C-mediated Sost expression. We hypothesized that Scriptaid may prevent 
HDAC4/5-mediated suppression of MEF2C and increase Sost expression. Ocy454-12H 
cells were treated with Scriptaid or PTH for 4 hours. Interestingly, Scriptaid significantly 
suppressed Sost (Fig. 19A), Mepe (Fig. 19C), Opg (Fig. 19D), Mef2c (Fig. 19F) 
expression and increased Rankl (Fig. 19B), Rankl/Opg ratio (Fig. 19I) and Hdac3 (Fig. 
19L). In contrast, dentin matrix protein 1 (Dmp1) (Fig. 19E), Hdac1 (Fig. 19J), Hdac2 
(Fig. 19K), Hdac4 (Fig. 19G) and Hdac5 (Fig. 19H) expression did not significantly 
respond to Scriptaid administration.  
As previously reported (Bakke, Bettaieb et al.), PTH significantly suppressed Sost (Fig. 
19M), Mepe (Fig. 19O), Opg (Fig. 19P) and Mef2c (Fig. 19Q) and significantly up-
regulated Rankl (Fig. 19N). Interestingly, whereas the degree of Sost and Mepe inhibition 
were similar between PTH and Scriptaid, PTH induced a much higher increase in Rankl 
expression compared to Scriptaid (~60-fold vs ~3-fold, Fig. 19A-C & M-O).  
Additionally, same as metabolic genes regulation, TSA showed effects similar to 
Scriptaid whereas MC1568 had no significant effect (Fig. 19S-T).  
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In summary, these data suggest that Scriptaid, similarly to PTH and TSA, may regulate 
bone remodeling by decreasing Sost expression and increasing Rankl expression. 
However, Scriptaid does not simply perform as Class II inhibitor, MC1568, in regulation 
of these genes. 
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Figure 19. Bone remodeling genes regulation by Scriptaid, PTH and other HDAc inhibitors in 
Ocy454-12H cells 
(A-L) Ocy454-12H cells were treated with Scriptaid prior to RNA isolation. Real-time qPCR for Sost, 
Rankl, Mepe, Opg, Dmp1, Mef2c, Hdac4, Hdac5, Rankl/Opg, Hdac1, Hdac2 and Hdac3 in Ocy454-12H 
cells treated with Scriptaid (1 µM) for 4 h, relative to β-actin. (M-R) Real-time qPCR for Sost, Rankl, Mepe, 
Opg, Mef2c and Rankl/Opg in Ocy454-12H cells treated with PTH (1 nM) for 4 h, relative to β-actin. (S-T) 
Real-time qPCR for Sost and Rankl in Ocy454-12H cells treated with TSA (1 µM) or MC1568 (1 µM) for 4 
h, relative to β-actin. Unpaired t-tests were performed for (A-R). One-way ANOVA were performed with 
the vehicle-treated cells as comparison groups for (S-T). For all graphs n=3 and *p<0.05 and ** p<0.01, 
data is expressed as means ± SD. 
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5.2.2 –Dose Response of The Bone Remodeling Genes to Scriptaid Treatment 
To investigate if Scriptaid regulation of osteocyte skeletal remodeling genes is also dose-
dependent, cells were treated for 4 hours at different concentrations (10 nM, 100 nM, 500 
nM, 1 µM and 10 µM) and the expression of key bone remodeling genes was analyzed. 
Consistent with our previous data, Scriptaid increased Rankl (Fig.  20B) and decreased 
Sost and Mepe expression (Fig. 20A & C) in a dose-dependent manner. The dose-
response analysis showed that 10 nM could significantly suppress Sost and Mepe, 
whereas 1 µM of Scriptaid could significantly up-regulate Rankl expression, which is the 
highest concentration needed for significant response among Glut4, Pdk4, Sost, Rankl, 
and Mepe genes expression. These data suggested that, same as metabolic genes, 
Scritpaid regulation to the bone remodeling genes in osteocytes is also enhanced as 






Figure 20. Bone remodeling genes dose response to Scriptaid 
Ocy454-12H cells were treated with Scriptaid prior to RNA isolation. Real-time qPCR for Sost, Rankl and 
Mepe dose response in cells treated with Scriptaid for 4 h, normalized to vehicle. One-way ANOVA was 
performed with the vehicle-treated cells as comparison.  For all graphs n=3 and *p<0.05; **p<0.01 and *** 
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5.3 – Study of Scriptaid effects on bone explants and primary osteocytes 
5.3.1 - Scriptaid Effects on Bone Explants and Primary Osteocytes 
To confirm that the effects of Scriptaid and PTH on the osteocytic cell line can also be 
observed in cultured bone tissue, we isolated osteocyte-enriched bone explants (OEBE) 
from 4 week-old wild type mouse calvaria (Baron and Kneissel) and treated them with 
Scriptaid or PTH for 6 hours prior to RNA isolation. Scriptaid significantly or marginally 
increased metabolic gene expression in calvaria explants including Glut4, Pdk4, Cs and 
Atp5d (P=0.07) (Fig. 21A-D), which closely related to glucose and lipid utilization and 
mitochondria activities. However, Scriptaid did not affect HkII and Glut1 expression (Fig. 
21E-F). Sost was significantly suppressed upon Scriptaid administration (Fig. 21G). 
Interestingly, unlike in vitro assays (Figs. 19 and 20), expression of Rankl was 
significantly but moderately suppressed (Fig. 21H). Other genes, such as Mepe, Opg and 
the Rankl/Opg ratio (Fig. 21I-K), were not significantly regulated.  
	    
	  


















Figure 21. Regulation of metabolic and bone remodeling genes by Scriptaid in OEBE 
OEBE from 4-week old WT female mice were treated with Scriptaid prior to RNA isolation. Real-time 
qPCR for OEBE Glut4, Pdk4, Cs, Atp-5d, HkII, Glut1, Sost, Rankl, Mepe, Opg and Rankl/Opg after 
Scriptaid (10 µM) administration for 6 h, relative to β-actin. For all graphs, unpaired t-test was performed, 











































































































































































































	   51 
By contrast to Scriptaid, PTH consistently decreased Sost, Mepe and Opg expression and 
increased both Rankl expression and the Rankl/Opg ratio (Fig. 22G-K), whereas PTH did 
not show any effect on metabolic genes in OEBEs (Fig. 22A-D) with the exception for a 
significant increase in HkII and marginal increase in Glut1 (P=0.06) (Fig. 22E-F). These 





































Figure 22. Regulation of metabolic genes and bone remodeling genes by PTH in OEBEs 
OEBEs from 4-week old WT female mice were treated with PTH prior to RNA isolation. Real-time qPCR 
for Glut4, Pdk4, Cs, Atp5d, HkII, Glut1, Sost, Rankl, Mepe, Opg and Rankl/Opg in OEBE treated with PTH 
(100 nM) for 6 h, normalized to β-actin. For all graphs, unpaired t-test was performed, n=5~6 and *p<0.05; 
** p<0.01 and *** p<0.001, data are expressed as means ± SD. 
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To further investigate if Scriptaid treatment has similar effects on primary cells, we 
isolated primary osteocytes from long bones of 4 week-old wild type male mice (Stern, 
Stern et al. 2012). The cells were treated with Scriptaid 4 hours prior to RNA extraction 
and real-time qPCR analysis. Scriptaid significantly increased Glut4 and decreased Sost 
expression (Fig. 23A-C), which are the key genes respectively reflecting osteocytes 
functions in bone and metabolism. However, Scriptaid did not significantly increase 






Figure 23 A-C. Regulation of metabolic genes and bone remodeling genes by Scriptaid in primary 
osteocytes 
Primary osteocytes from 4-week old WT male mice were treated with Scriptaid prior to RNA isolation. 
Real-time qPCR for Glut4, Sost and Rankl in primary osteocytes treated with Scriptaid (10 µM) for 4 h, 
relative to β-actin. For all graphs, unpaired t-test was performed, n=3 and *p<0.05; ** p<0.01 and *** 
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5.4 – Molecular mechanisms by which Scriptaid regulates the metabolism and 
bone remodeling genes expression in osteocytes 
5.4.1 – Scriptaid Effects on HDAC4/5 Subcellular Translocation and HDAC4/5-
MEF2C Binding Affinity 
Next, we sought to investigate the underlining mechanisms by which Scriptaid regulates 
gene expression in osteocytes. We have previously shown that, in these cells, PTH 
suppression of Sost is mediated by HDAC4/5 nuclear translocation and inhibition of 
MEF2C function (Azuma, Ito et al. 2001). Treatment with Scriptaid did not affect 
HDAC4 subcellular translocation (Fig. 24A-B), but significantly promoted HDAC5 
accumulation in the nucleus (Fig. 24C-D), suggesting that Scriptaid-mediated 
suppression of Sost is through HDAC5-dependent mechanisms. However, in muscle cells, 
Scriptaid blocks HDAC complex formation and induce HDAC4/5 cytoplasmic 
translocation. We hypothesized that Scriptaid regulates osteocyte metabolism function 
through a different mechanism. 
To further investigate whether Scriptaid controls Sost expression by promoting HDAC5 
nuclear translocation and binding to MEF2C, we performed co-immunoprecipitation with 
whole cell protein lysates. Anti-MEF2C and anti-HDAC5 antibodies were respectively 
utilized to precipitate the protein complex. Consistent with previous data, both 
immunoprecipitations for MEF2C and HDAC5 show that Scriptaid significantly 
increased HDAC5 binding to MEF2C (Fig. 24E and G-I) but did not affect the binding of 
HDAC4 to MEF2C (Fig. 24E-F). 
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These results indicated that, similar to PTH, Scriptaid promotes HDAC5 translocation 
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Figure 24. HDAC4/5 subcellular translocation and HDAC4/5 binding to MEF2C in response to 
Scriptaid in Ocy454-12H cells 
(A-D) Western blot analysis for subcellular protein fractions of HDAC4 (A) and HDAC5 (C) in Ocy454-
12H cells treated with Scriptaid (10 µM) for 1 h prior to subcellular protein fractions isolation. Nuclear 
proteins were normalized to SP1, cytoplasmic proteins were normalized to tubulin. Quantification for the 
nuclear/cytoplasmic ratio of HDAC4 (B) and HDAC5 (D), normalized to SP1 and tubulin. (E-I) Ocy454-
12H cells were treated with Scriptaid (10 µM) for 1 h prior to protein isolation. Coimmunoprecipitation of 
MEF2C IP to HDAC4/5 (E) and HDAC5 IP to MEF2C (H). Quantification for coimmunoprecipitation of 
HDAC4 (F) and HDAC5 (G) binding to MEF2C, normalized to MEF2C; MEF2C (I) binding to HDAC5, 
normalized to HDAC5. For all graphs, unpaired t-test was performed, n=3-4 and *p<0.05; ** p<0.01 and 
*** p<0.001, data are expressed as means ± SD. 
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5.4.2 – The Role of HDAC5 in Mediating Scriptaid Effects in Osteocytes 
To investigate the role of HDAC4/5 in Scriptaid-mediated gene regulation, we generated 
Ocy454-12H cells lacking either HDAC4 or HDAC5 by using CRISPR/Cas9 and shRNA 
techniques. Western blot analyses demonstrated the efficient deletion of these proteins 
(Fig. 25A, G). Our data showed that the deletion of HDAC4 did not impair the Scriptaid 
mediated regulation of Sost and Glut4 expression (Fig. 25D-F), demonstrating that 
mechanisms other than HDAC4 must be involved.  
Additionally, Ocy454-12H cells lacking MEF2C expression were generated with shRNA 
techniques for further validation. Our data showed that silencing of MEF2C potently 
reduced Sost basal expression (Fig. 25G-H). Also MEF2C knockdown had no effect on 
Glut4 baseline expression and did not block cells’ response to Scriptaid treatment (Fig. 
25I). These data further validated that Scriptaid regulation to Glut4 in osteocytes is 

























Figure 25. Gene regulation by Scriptaid in Ocy454-HDAC4 KO cells and Ocy454-12H-shMEF2C 
cells.  
(A) Western blot analysis of HDAC4 and HDAC5 in HDAC4 KO cells for characterization, 
MW=molecular weight. (B-D) Real-time qPCR for basal Pdk4, Cs and Atp5d in control and HDAC4 KO 
cells. (E-F) Real-time qPCR for Sost and Glut4 in control and HDAC4 KO cells treated with Scriptaid (100 
nM, 500 nM) for 4 h. (G-H) Real-time qPCR for basal Mef2c and Sost in control and shMEF2C cells, 
relative to β-actin. (I) Real-time qPCR for Glut4 in control and shMEF2C cells treated with Scriptaid (500 
nM) for 4 h, relative to β-actin. Unpaired t-test was performed for (B-D, G-H). T-test within the same cell 
line was performed for (E-F, I). For all graphs, n=3 and *p<0.05, ** p<0.01 and *** p<0.001, data are 
expressed as means ± SD. 
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In contrast, the silencing of Hdac5 significantly increased Sost baseline expression (Fig. 
26A) and impaired its suppression in response to Scriptaid (Fig. 26K). As shown in Fig. 
26F and L, expression or up-regulation of Glut4 upon Scriptaid treatment were still 
present in shHDAC5 cells. In addition, Hdac5 silencing decreased Dmp1 (Fig. 26E) and 
showed no significant effects on Rankl, Mepe, Pdk4, Cs, Atp-5d and HkII genes basal 
expression (Fig. 26C-D and G-I). Collectively, these results demonstrated that in 
osteocytes Sost regulation is associated with HDAC5 nuclear translocation in osteocytes, 
































Figure 26. Metabolic and bone remodeling genes regulation by Scriptaid in Ocy454-shHDAC5 Cells 
(A) Western blot analysis for HDAC4 and HDAC5 in shHDAC5 cells, MW=molecular weight. (B-J) Real-
time qPCR for basal Sost, Rankl, Mepe, Dmp1, Glut4, Pdk4, Cs, Atp5d and HkII in control and shHDAC5 
cells. (K-L) Real-time qPCR for Sost and Glut4 in control and shHDAC5 cells treated with Scriptaid (100 
nM, 500 nM) for 4 h, normalized to β-actin. Unpaired t-test was performed for (B-J), One-way ANOVA 
multiple comparison tests within sample cell line were performed for (K-L) with the vehicle-treated cells as 
comparison. For all graphs, n=3 and *p<0.05; ** p<0.01 and *** p<0.001, data are expressed as means ± 
SD. 
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5.4.3 – The Scriptaid Effects on SIK2/CRTC2 in Osteocytes 
Since HDAC4/5 do not mediate Scriptaid induced Glut4 gene up-regulation, we sought to 
explore alternative factors. It has been previously reported that SIK2 and its downstream 
target protein CRTC2 have been shown to play critical roles in regulating Glut4 gene 
expressions in adipocytes (Buo and Stains) and Rankl expression in osteocytes (Azuma, 
Ito et al.). We hypothesize that Scriptaid might regulate Glut4 expression through the 
SIK2/CRTC2 signaling pathway. Western Blot analysis of subcellular localization of 
CRTC2 revealed nuclear translocation and accumulation upon Scriptaid treatment (Fig. 
27A-B), suggesting that Scriptaid might have an off-target effect functioning as a kinase 






Figure 27. CRTC2 subcellular localization in response to Scriptaid in Ocy454-12H cells 
(A) Western blot analysis of CRTC2 in Ocy454-12H cells treated with Scriptaid (10 µM) for 1 h, nuclear 
protein normalized to SP1, cytoplasmic protein normalized to tubulin. (B) Quantification of the 
nuclear/cytoplasmic CRTC2 ratios, nuclear protein normalized to SP1, cytoplasmic protein normalized to 
tubulin. An unpaired t-test was performed for (B). For the graph, n=3 and *p<0.05, data are expressed as 
means ± SD.  
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To investigate whether the SIK2/CRTC2 signaling pathway mediates Glut4 up-regulation, 
Sik2 (shSIK2) and Crtc2 (shCRTC2) expression were silenced with shRNA in Ocy454-
12H cells (Fig. 28A-B). Interestingly, shSIK2 and shCRTC2 cells significantly reduced 
their basal expression of Sost (Fig. 28C). However, silencing of Sik2 and Crtc2 did not 
significantly affect any other bone remodeling genes such as Rankl and Mepe (Fig. 28D-
E) or metabolic gene expression including Pdk4, Atp5d, Cs and HkII (Fig. 28F-I). Both 
low (100 nM) and high (500 nM) doses of Scriptaid administration significantly 
increased Glut4 expression in shSIK2 and shCRTC2 cells (Fig. 28J), suggesting the 
mediating mechanism might be independent of SIK2/CRTC2. 
 
	    
	  

















Figure 28. Regulation of metabolic genes and bone remodeling genes by Scriptaid in Ocy454-12H-
shSIK2 and Ocy454-12H-shCRTC2 cells 
(A-I) Real-time qPCR for basal, Sik2, Crtc2, Sost, Rankl, Mepe, Pdk4, Atp5d, Cs and HkII in control, 
shSIK2 and shCRTC2 cells. (J) Real-time qPCR for Glut4 in control, shSIK2 and shCRTC2 cells treated 
with Scriptaid (100 nM, 500 nM) for 4 h, normalized to β-actin. One-way ANOVA was performed for (A-
I). One-way ANOVA multiple comparison test within the same cell line was performed for (J). For all 
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5.4.4 – Glut4 Promoter Luciferase Reporter Assay 
To explore alternative mechanisms by which Scriptaid regulates Glut4 expression, we 
searched for additional putative transcription factor (TF) binding sites in the mouse Glut4 
gene promoter region. The majority of the known TF binding sites are located within the 
1300bp 5’ upstream of the Glut4 transcription starting site. Three fragments of the Glut4 
promoter (sequence spanning GLUT4 1.3kbp: -1239 bp ~ +34 bp; GLUT4 0.8kbp: -756 
bp ~ +34 bp; GLUT4 0.5 kbp: -463 bp ~ +34 bp) were cloned into pGL3-basic luciferase 
reporter vector and luciferase activity was detected and analyzed (Fig. 28A). Scriptaid 
significantly increased luciferase activity driven by the GLUT4 1.3kbp promoter (~2.5 
folds) compared to the truncated 0.8 kbp and 0.5 kbp fragments (1 fold), suggesting that 
the sequences between -1239 bp ~ -756 bp and -463 bp ~ 0 bp mediate Scriptaid up-
regulation of Glut4 (Fig. 29B). 
The -1239 bp~-463 bp region contains both IRE (O/E&NF1) and MEF2 binding sites. 
We, therefore, individually mutated or deleted these regions (Fig. 29C). The mutation of 
the IRE region significantly reduced Scriptaid-mediated Glut4 regulation whereas 
mutation of the MEF2 region had no effect (Fig. 29D). This suggests that IRE, but not 
MEF2, is important for Scriptaid-induced Glut4 expression. Next, we generated GLUT4 
1.3 kbp vectors in which the O/E&NF1 binding site (O/E&NF1-Del) or the whole IRE 
region (IRE-Del) were deleted (Fig. 29E). Consistent with our previous data, both the 
O/E&NF1-Del and the IRE-Del significantly reduced luciferase activity upon Scriptaid 
treatment (Fig. 29F), indicating that the IRE (O/E&NF1) region is required for Glut4 
regulation by Scriptaid. Finally, GLUT4 1.3kbp luciferase plasmid with deletion of 3 
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transcription factors binding sites including SP1, SREBP1c and C/EBPα (3TF-Del) was 
generated for validation (Fig. 29G). 3TF deletion also impaired Scriptaid upregulation 
(Fig. 29H). These data indicated O/E&NF1 and 3 transcription factors binding sites play 
important roles in Scriptaid-mediated increase of Glut4 expression. 
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Figure 29. GLUT4 promoter luciferase regulation by Scriptaid 
(A) Schematic diagrams of the design for GLUT4 promoter with 1300 bp, 800 bp or 500 bp length. (B) 
Quantification of luciferase activity mediated by the 1300bp, 800bp or 500bp GLUT4 promoter plasmid in 
12H cells treated with Scriptaid (10 µM) for 4 h, normalized to co-transfected Renilla luciferase activity. 
(C-H) Schematic diagram of the Glut4 promoter with O/E&NF1 or MEF2 binding sites mutation (C), 
O/E&NF1 or IRE deletion (E), 3TFs (SP1&SREBP1c&C/EBPα) deletion (G). Quantification of the 
luciferase activity of O/E&NF1 or MEF2 binding site mutants (D), O/E&NF1 or IRE deleted (F), 3TFs 
(SP1&SREBP1c&C/EBPα) deleted (H) Glut4 promoter plasmid in 12H cells treated with Scriptaid (10 µM) 
for 4 h, normalized to co-transfected Renilla luciferase activity. Two-way ANOVA with Tukey’s multiple 
comparison test was performed for (B, D, F, H) and vehicle-treated samples as comparison. For all graphs, 
n=3 and *p<0.05; ** p<0.01 and *** p<0.001, data are expressed as means ± SD. 
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Vorinostat SAHA is an FDA approved Scriptaid derivative medicine for cutaneous T-cell 
lymphoma (CTCL) that is available in the market. Thus, we hypothesized that Vorinostat 
has similar effects on metabolic and bone-remodeling genes in osteocytes, which might 
benefit the patients’ metabolism and bone structure. Administration of Vorinostat also 
significantly increased luciferase activity driven by the GLUT4 1.3Kb promoter (Fig. 30).  







Figure 30. Glut4 promoter luciferase response to Vorinostat 
Quantification for luciferase activity mediated by the 1300 bp Glut4 promoter in 12H cells treated with 
Vorinostat (10 µM) for 4 h, normalized to co-transfected Renilla luciferase activity. Unpaired t-test was 
performed. For the graphs, n=3 and *p<0.05, data are expressed as means ± SD. 
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To further validate our hypothesis, we generated Ocy454-12H cells in which C/EBPα 
was silenced by shRNA (Fig. 31A). In these cells, up-regulation by Scriptaid was 
significantly reduced (~7 fold to ~2 fold) (Fig. 31B), further indicating that C/EBPα 
located at 3TF binding sites partially plays an important role in the Scriptaid-mediated 







Figure 31. Glut4 gene regulation by Scriptaid in Ocy454-12H-shC/EBPα cells 
(A) Real-time qPCR for C/EBPα in control and shC/EBPα cells. (B) Real-time qPCR for Glut4 in control 
and shC/EBPα cells treated with Scriptaid (500nM) for 4 h. An unpaired t-test was performed for (A). 
Two-way ANOVA with Tukey’s multiple comparison test was performed for (B) with the vehicle-treated 
samples as comparison. For all graphs, n=3 and *p<0.05, ** p<0.01 and *** p<0.001, data are expressed as 
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5.5 – Explore the effects of Scriptaid on gene expression in Gsα KO osteocytes 
5.5.1 – Scriptaid Effect on Osteocytes with Gsα Deletion 
Several Gsα coupled receptors are expressed on the osteocyte cell surface. They 
compromise receptors for several hormones and cytokines such as PTH and PGE2, 
mediating their effects in osteocytes. To test if Scriptaid regulates gene expression in 
osteocytes independent from Gsα signaling, we generated Ocy454 Gsα-KO cells through 
the CRISPR-Cas9 system. Control cells and Gsα-KO cells were treated with Scriptaid or 
PTH for 4 hours prior to the gene analysis. Scriptaid significantly alter the expression of 
the Glut4, Atp5d, Pdk4, Sost and Mepe genes in Ocy454-GsaKO cells (Fig. 32A & C-F). 
In addition, Scriptaid significantly up-regulated Rankl expression in Gsα-KO cells but not 
in control cells (Fig. 32B). However, PTH had no effect on these cells (Fig. 32G-L). 
These data further indicate Scriptaid regulates osteocyte metabolic and bone-remodeling 
genes independently from activation of Gsα-protein-coupled receptors, including PTH 
receptor. Moreover, it suggests Scriptaid may rescue animals’ osteopenia bone phenotype 
induced by Gsα signaling deficiency 
 
	    
	  
















Figure 32. Gene regulation by Scriptaid and PTH in Ocy454-Gsα KO cells 
Ocy454-Gsα KO cells were treated with Scriptaid or PTH prior to RNA isolation. Real-time qPCR for Sost 
(A), Rankl (B), Glut4 (C), Pdk4 (D), Atp5d (E), Mepe (F) in cells treated with Scriptaid (1 µM) and Sost 
(G), Rankl (H), Glut4 (I), Pdk4 (J), Atp5d (K), Mepe (L) in cells treated with PTH (1 nM) for 4 h, 
normalized to vehicle-treated cells. For all graphs, Two-way ANOVA with Tukey’s multiple comparison 






























































































































































































































































































































































































































	   72 
6 – Discussion 
6.1 – Glucose Metabolism and Bone Remodeling 
The adult skeleton maintains its structural integrity by continuous remodeling; i.e. the 
highly orchestrated coupling of bone formation and bone resorption. Remodeling is 
regulated by environmental factors (load), hormones, cytokines and nutritional cues and 
it requires energy in the form of glucose. Indeed, glucose metabolism is a critical 
component of skeletal metabolism and bone cells, mostly osteoblasts, take up one-fifth of 
the glucose consumed by muscles. These cells sense and use glucose through a GLUT1 
and AMPK-dependent pathway independent of insulin signaling(Wei, Shimazu et al. 
2015). Osteoblasts require glucose for their differentiation and collagen synthesis, which 
are critical for bone formation. In turn, these cells act as an integral component of the 
whole-body glucose homeostasis by secreting growth factors and hormones, like 
osteocalcin, which, in its undercarboxylated form, regulates pancreatic insulin secretion.   
Opposing what was stated before, results from our studies show for the first time a 
distinctive glucose utilization mechanism that happens in osteocytes, in which Scriptaid 
increases Glut4 rather than Glut1 expression. Compared to GLUT1, an insulin 
independent glucose transporter, the expression on cell surface of GLUT4 is more 
dependent on insulin stimulation. This suggests glucose metabolism in osteocytes may be 
more dependent on insulin stimulation. This study provides a novel insight into diabetes 
as a large number of the patients show reduced Glut4 gene expression (Gaster, Staehr et 
al. 2001). Interestingly, our preliminary data (not shown) suggested insulin treatment did 
not significantly change Glut4 expression in Ocy454-12H cells regardless of the length of 
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the treatment. One possible explanation is due to in vitro study limitation since the 
previous study indicated that insulin could regulate Glut4 expression in opposite 
directions in muscle cells in vitro compared to in vivo studies (Im, Kwon et al. 2007). 
Another consideration of GLUT4 activity is the protein subcellular localization. As 
mentioned in the introduction, the active GLUT4 expressed on the cell membrane surface 
is capable of glucose transportation and utilization. The exocytosis and endocytosis are 
important processes that determine GLUT4 protein post-translational activity. Several 
factors regulate GLUT4 subcellular translocation and they can be a potential target to 











Figure 33. Some factors regulating GLUT4 translocation 
S Huang, et al, Cell Metabolism, 2007 
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6.2 – Osteocytes Functions and Energy Metabolism 
Osteocytes, which are deeply embedded in the mineralized bone matrix, are the most 
abundant cell type in the adult skeleton, accounting for 95%~98% of all bone cells. As 
previously stated, they have emerged as the main orchestrators of both osteoblast and 
osteoclast activities through the secretion of endocrine and paracrine factors such as 
sclerostin, DMP1, PHEX, RANKL and OPG.  
However, despite their key role in skeletal and whole-body homeostasis, a limited 
number of studies focus on osteocytes’ respiration and metabolism. Still, the energy 
consumption and glucose metabolism of these cells remain unclear. Here we 
demonstrated that Scriptaid could stimulate respiration and metabolic activity in 
osteocytes partially through the up-regulation of Glut4. Scriptaid effects on Glut4 in 
osteocytes imply that osteocytes may regulate their respiration and metabolism 
differently than osteoblasts do, which mainly depend on Glut1. Additionally, although 
moderately, Scriptaid significantly increases the genes closely related to lipid utilization 
(Pdk4) and mitochondrial activities (Cs & Atp-5d). Their contribution to osteocyte 
metabolism increments and subsequent effects need further investigation. 
6.3 – HDAC4/5 and Glucose Metabolism 
HDACs are a family of enzymes that facilitate acetyl removal from lysine residues on 
histones. HDACs are divided into 4 classes (class I, II, III & IV) with HDAC 4 and 5 
belonging to class II (Gaur, Connor et al.). HDAC4 and 5 lack strong catalytic capability 
and they form complexes with class I HDACs, such as HDAC3, to inhibit transcription 
factors. In bone, several studies have indicated that HDACs play an important role in 
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skeletal homeostasis (Balemans, Ebeling et al.). HDAC3 binds to RUNX2 and reduce 
osteocalcin expression (Bonewald) whereas conditional deletion of HDAC3 in 
osteoblasts and osteocytes accelerates age-dependent  bone loss (Balemans, Patel et al.). 
HDAC4 inhibits RUNX2 and regulates endochondral bone formation (Kringelbach, 
Aslan et al.). In osteocytes, PTH activates its receptor PTHR. Through several 
intermediate factors, this process finally induces HDAC4/5 dephosphorylation and their 
translocation into the nucleus where they bind to and inhibit MEF2C with subsequent 
Sost suppression (Esen, Lee et al. 2015). Consistent with the pathway described, 
HDAC5-null mice have increased sclerostin expression and reduced trabecular bone 
(Bonewald) and deletion of HDAC5 in Ocy454 cells significantly increase Sost 
expression (as shown in Fig.6C). In adipocytes and skeletal muscle cells, HDAC4/5 
inhibit MEF2 and suppress the expression of subsequent metabolic genes especially 
Glut4 (Im, Kwon et al. 2007, Henriksson, Säll et al. 2015, Gaur, Connor et al. 2016, Gaur, 
Connor et al. 2017).  
Previous studies indicated HDAC4/5-MEF2 pathway controls Sost expression in 
osteocytes and mediates Scriptaid induced Glut4 up-regulation in skeletal muscle cells.  
However, our study suggests that in osteocyte HDAC4/5-MEF2 may only participate in 
Scriptaid induced Sost suppression. We postulate that Scriptaid-induced up-regulation of 
GLUT4 might be mediated by an independent mechanism. Several speculations may 
explain this phenomenon. First, osteocytes are different from myocytes and adipocytes, 
which suggests the same gene regulatory effects might be mediated through different 
subcellular mechanisms in different cell types. Second, as an inhibitor, Scriptaid may 
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have certain off-target interactions or side effects that activate or inhibit different signal 
pathways in distinct cell types. Additionally, TSA, a highly specific Class I HDAC 
inhibitor, showed similar effects suggesting that Scriptaid acts as a Class I HDAC 
inhibitor in osteocytes other than Class II HDAC complex blocker. 
6.4 – Canonical Effects of Scriptaid 
In previous studies, Scriptaid was shown to have a weak direct inhibitory effect on 
HDAC3 and to a certain extent HDAC4/5 on their deacetylation activity (Gaur, Connor et 
al. 2016), positioning Scriptaid as a novel atypical inhibitor of HDACs. Fortunately, 
Scriptaid had low toxicity to cells compared to TSA (Gaur, Connor et al. 2016). However, 
in muscles and adipose tissues, Scriptaid prevents HDAC4/5 from forming the complex 
with HDAC3, NCOR, and SMRT, indirectly blocking the complex inhibition to MEF2. 
Once MEF2 is reactivated, it binds to and induces the transcription of its target genes. 
Scriptaid can, therefore, have a positive and incremental change in cell metabolism by 
indirectly activating the cell metabolism and respiratory genes related to MEF2. 
6.5 – Effects of Scriptaid and PTH in Osteocytes; Similarities and Differences 
Scriptaid was shown to have a weak affinity to class I HDACs but instead works as an 
inhibitor for the co-repressor complex (Manglik and Kruse 2017). In osteocytes, however, 
Scriptaid induces the nuclear translocation of HDAC5 and suppresses MEF2C activity, 
effectively down-regulating Sost expression. This implies that different cell types form 
different HDAC complexes with opposing effects. On one hand, Scriptaid and TSA 
promote HDAC5 nuclear translocation and MEF2C inhibition in osteocytes, whereas on 
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the other hand, Scriptaid promotes MEF2 transcription in skeletal muscle (Bonewald).  
We speculate that these opposite effects might be due to differing co-factors or co-
repressors specifically expressed in bone or muscle tissues. Another possibility is that 
part of the Scriptaid and TSA inhibitory effect is mediated by class I HDACs, such as 
HDAC3. However, our preliminary data (not shown) showed Scriptaid treatment did not 
induce a significant HDAC3 nuclear translocation in osteocytes, suggesting that other co-
factors might be involved.  
In the Ocy454-12H cells, both PTH and Scriptaid increase energy metabolism and 
glucose utilization through an HDAC4/5-independent mechanism. Alternatively, in 
myocytes, Glut4 expression is MEF2 dependent (Bonewald), whereas in adipocytes 
Glut4 is suppressed through HDAC4- and CTRC2-dependent mechanisms (Gaur, Connor 
et al.). However, in our study, deletion of either HDAC4/5 or CRTC2 did not affect the 
Scriptaid-induced Glut4 up-regulation, leading us to propose a different regulatory 
mechanism.   
Several hormones, particularly PTH, promote bone anabolism, in part in osteoblasts, by 
stimulating anaerobic glycolysis while suppressing glucose oxidation through the TCA 
cycle. In osteocytes, PTH exerts its bone-forming effect by suppressing Sost through 
dephosphorylation and nuclear translocation of HDAC4 and 5, which inhibits MEF2C, 
suggesting that PTH (or other factors) might also affect osteocytes metabolism. 
In OEBEs, PTH did not significantly regulate the expression of metabolic genes 
including Glut4, Pdk4, Atp5d and Cs as it did in Ocy454-12H cells, and only moderately 
regulated HkII expression. Several factors can account for the differences between the in 
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vitro and the ex vivo effects. First, PTH bioavailability might be different between in vitro 
and ex vivo conditions and the dose and time used in this experiment might not be 
optimal to elicit PTH maximal effects. Second, although OEBE is a well-accepted 
osteocyte-rich model, other cells might still be present (such as osteoblasts, marrow 
adipocyte, endothelial cells, fibroblast or other mesenchymal cells) that might not 
regulate metabolic gene expression in response to PTH treatment. Indeed, a recent 
publication showed PTH treatment suppresses Glut4 expression and insulin-stimulated 
glucose uptake in differentiated 3T3-L1 adipocytes (28).  
One limitation of our experiment is that only relative changes in gene expression were 
analyzed. Any real-time PCR experiment has an intrinsic variability that can be improved 
by including a panel of endogenous controls (or housekeeping genes) to correct for 
sample variation. In our experiments, all data were normalized to a single housekeeping 
gene, β-Actin, based on initial studies demonstrating that this gene did not significantly 
change in Ocy454-12H cells upon Scriptaid treatment. Nevertheless, we cannot exclude 
that some of the variability among the real-time data might be due to changes in the 
reference gene. 
In summary, we have reported here for the first time that Scriptaid, an HDAC complex 
disruptor, can significantly suppress Sost and Mepe expression and, at the same time 
induce osteocyte respiration and glucose uptake. Similar effects were also observed under 
PTH treatment. It suggests that Scriptaid and PTH partially share common signaling 
mechanisms. We can speculate that Scriptaid induces exercise-like responses both in 
muscle and in bone, and might be a good candidate for the treatment of disuse-induced 
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osteopenia and muscle atrophy. Additional studies are needed to demonstrate the 
therapeutic efficacy of this compound in vivo. Currently, some Scriptaid derivatives like 
Vorinostat are approved for the treatment of hematologic diseases, suggesting that, in 
these conditions, the drug might also protect the skeleton form detrimental bone loss.  
6.6 – Effects of Scriptaid in vitro and ex vivo Models 
Ex vivo OEBEs closely recapitulate skeletal processing and were used, in this study, to 
determine the effects of both Scriptaid and PTH. Both drugs suppressed the expression of 
Sost and Mepe, suggesting an anabolic effect. Interestingly, Rankl was also significantly 
suppressed by Scriptaid in OEBEs whereas it was increased in Ocy454-12H cells. PTH, 
in contrast, had similar effects both in vitro and ex vivo. It is important to note that the 
induction of Rankl expression differs in magnitude between Scriptaid and PTH, with the 
latter having a much greater increase (approximately 3 and 60 fold respectively). This 
blunted Rankl activation by Scriptaid might be beneficial to the bone. We don’t have an 
explanation of the opposite regulation of Rankl by Scriptaid in our two experimental 
models. We can speculate that in ex vivo bone explants, other cells, such as endosteal or 
periosteal osteoblasts or endothelial cells, might contribute to the regulation of this 
transcript. It is crucial to consider that the relative expression of Rankl varies among 
these different experimental models with OEBEs having the highest expression of the 
transcript (~250 fold to Ocy454-12H and ~50 to primary osteocytes). It suggests that 
cells with high Rankl expression might be potentially less sensitive to its regulation by 
Scriptaid. Also, other Rankl expressing cells, besides osteocytes, might differentially 
regulate Rankl in response to Scriptaid treatment. Moreover, it is necessary to note that 
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PTH stimulation of Rankl expression was also blunted in OEBE, with only a 3-fold 
increase in expression compared to the 60-fold increase present in Ocy454-12H cells.   
Finally, the difference in gender of the animals where we isolated cells or tissues from 
should be also taken into consideration since Ocy454-12H cells and OEBE were from 
female mice and primary osteocytes were isolated from male mice. The mouse genome 
database indicates none of the genes detected in our OEBE experiment (Glut4, Pdk4, 
Atp5d, Cs, HkII, Glut1, Sost, Rankl Opg and Mepe) are located in mouse sex 
chromosomes. However, we still cannot completely rule out the gender factor since 
different hormonal levels between male and female animals may directly or indirectly 
affect tissues’ or cells’ responses to Scriptaid administration. Moreover, the distinctive 
subcellular mechanism or receptors expressed on cell surface between cells from male 
and female mice may induce completely cell response to chemical treatment. Further 
studies will be needed to further investigate potential effects of gender (Fulzele, Lai et al. 
2017). 
6.7 – Vorinostat Effect on Cancer Cell Metabolism and Viability 
Vorinostat, also known as suberanilohydroxamic acid (SAHA) or Zolinza as a 
commercial name, is a Scriptaid derivative that has been approved by FDA for CTCL 
(Payne, Smith et al. 2007). In addition, studies in some other laboratories indicated 
Vorinostat may also be used to treat other tumors including osteosarcoma, breast cancer, 
hepatocellular cancer, and others (Luu, Morgan et al. 2008, Mu, Brynien et al. 2015, Liu, 
Sun et al. 2018). In our study, we demonstrate that Vorinostat, similar to Scriptaid, 
stimulates osteocyte respiration and metabolism. 
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Although the Vorinostat effect on cell metabolism might be beneficial for cell viability 
and function, this effect seems to stimulate tumor cells proliferation and metastasis, 
which is contradicting its anti-cancer function. One possible explanation is the different 
respiration status: aerobic respiration and anaerobic respiration. Previous studies have 
shown that most of the cancer cells use glycolysis and anaerobic respiration as their 
major metabolic activity due to their rapid and unrestricted growth. However, our study 
suggests the increase in energy consumption rate is mainly induced by mitochondrial 
aerobic respiration. Another study showed Vorinostat could prevent hypoxia-induced 
smooth muscle cell growth, which is consistent with our results. The second potential 
reason might be different mechanisms for drug targeting. Even though the cell respiration 
rate is enhanced, other genes like the tumor suppressors p53 and p21 may also be 
potently regulated by Vorinostat that leads to cell cycle arrest and apoptosis. Vorinostat 
could also down-regulate the expression of immuno-suppressive genes such as 
interleukin-10 (IL-10) and angiogenesis genes such as vascular endothelial growth factor 
(VEGF) and hypoxia-inducible factor 1α (HIF-1α). In this case, the drug could sensitize 
the cancer immune system and block the tumor angiogenesis. The third possible reason 
might be due to the drug dosage. In our study Vorinostat is only applied in relative low 
dose (1-10 µM), whereas in clinical treatment the recommended dosage is 6 mg/kg/day. 
Another study also indicated 50 µM of Vorinostat could significantly suppress 
osteosarcoma cell PPAR gamma coactivator 1α (PGC-1α) expression, which is also the 
key marker for mitochondria activity (Mu, Brynien et al. 2015).  
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6.8 – Clinical Relevance and Future Direction 
Scriptaid itself has not been developed for pharmaceutical applications, although 
Scriptaid derivatives have been approved by the FDA for treating tumor and other 
diseases, such as cardiovascular disease and Huntington's disease. Vorinostat has been 
used to treat CTCL during or after two systemic therapies when the disease relapses, 
aggravates or there are no signs for symptom relief (Payne, Smith et al. 2007). Other 
studies indicated Scriptaid is also able to inhibit cell growth of breast cancer, ovarian 
cancer, hepatocellular cancer and multiple myeloma (Giacinti, Giacinti et al. 2012, 
Damaskos, Valsami et al. 2017, Janyst, Janyst et al. 2018, Liu, Sun et al. 2018, Yao, Han 
et al. 2018). Several studies suggested that apart from anti-cancer function, Scriptaid or 
its derivative might also execute other beneficial effects like simulating exercise-like 
reaction, enhancing insulin sensitivity, protecting cardiocyte and attenuating traumatic 
brain injury (Wang, Jiang et al. 2013, Gaur, Connor et al. 2016, Gaur, Connor et al. 2017). 
It makes Scriptaid and its derivatives as a promising field for cancer medicine that not 
only prevent tumor growth and metastasis but also improve the patients’ general quality 
of life. Here we explored the effects of Scriptaid on bone formation since we 
hypothesized that due to activated MEF2 function, it will increase osteocyte sclerostin 
secretion and stimulates a catabolic reaction in skeletal tissue. Surprisingly, other than 
increase, Scriptaid potently decreases Sost expression in osteocytes both in vitro and ex 
vivo. Although it still significantly increased the Rankl/Opg ratio which suggests 
increasing osteoclast activity, it may act like PTH, which accelerates the general bone 
remodeling process and can induce bone anabolic reaction. 
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7 – Conclusion 
1. Scriptaid stimulates osteocytes metabolism and cell respiration 
2. Scriptaid suppresses osteocytes Sost gene expression and has a profound effect on 
several skeletal homeostasis genes expression. 
3. Scriptaid suppresses Sost expression through HDAC5 nuclear translocation, whereas it 
increases Glut4 expression through regulating O/E&NF1 and 3TFs promoter binding 
affinity. 
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8 – Future Plans 
(1) What are the effects of  Scriptaid on skeletal metabolism in vivo? 
 Optimize and perform mouse in vivo experiments to determine the Scriptaid effects 
  
(2) Since Scriptaid induces HDAC5 binding to MEF2C and suppresses Sost, which is 
downstream of the PTH receptor, can Scriptaid rescue the osteopenia present in 
mice lacking Gsα expression in osteocytes? 
 Administered Dmp1-Cre; Gsαfl/fl mice with Scriptaid and characterize their skeletal 
phenotype compared to vehicle treated ones 
  
(3) Does Scriptaid increase bone insulin sensitivity in diabetic mice? 
OEBE or primary osteocytes from diabetic mice (eg. NONcNZO10/LtJ mice or 
TALLYHO/JngJ mice) can be treated with Scriptaid and insulin. Determine the tissue 
glucose uptake capability. 
  
(4) Do the other up-regulated metabolic genes contribute to the increment of 
osteocyte mitochondrial respiration by Scriptaid? 
Generate Ocy454-12H cells lacking the Glut4 gene. Treat the cells with Scriptaid prior to 
the seahorse mitochondrial stress test. 
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